Global Immune Repertoire Sequencing Market Size Report Segmented by Product (Assay Kit & Reagent, Instruments, Software), Technology (Sequencing, Library Preparation), Application (Cancer Immunotherapy, Infectious Diseases, Vaccine Development), Forecast to 2031

The global immune repertoire sequencing market size is expected to grow at a CAGR of 10% during the forecast period. Advancements in sequencing technologies, expanding use of cancer immunotherapies, increasing government investments in genomics research, and the rising prevalence of chronic and infectious diseases are key driving factors supporting the market growth. 

Immune Repertoire Sequencing (IRS) refers to advanced genomic techniques used to analyze the diversity and composition of B-cell and T-cell receptors within the adaptive immune system. This method enables complete characterization of immune responses by interpreting the various sequences of immune receptors that recognise and fight infections, cancer cells, and autoantigens. High-throughput next-generation sequencing (NGS) systems are used for IRS in clinical diagnostics and immunology research. Some common types of immune repertoire sequencing include T-cell Receptor (TCR) Sequencing, B-cell Receptor (BCR) Sequencing, and Bulk Sequencing

To learn more about this report, download the PDF brochure

Rising demand for cancer immunotherapy and precision medicine fuels the demand for immune repertoire sequencing

A major factor driving demand for immune repertoire sequencing is the rising demand for cancer immunotherapy and precision medicine. Cancer has become more prevalent globally, and there is a shift towards personalized medicine, wherein IRS is crucial for identifying minimal residual disease (MRD), predicting therapy response, and identifying immunological markers. This detailed immune profiling allows clinicians and researchers to understand how individual patients- immune systems interact with tumors at the molecular level.

An article published by the World Health Organization reported that there were 20 million new cases of cancer and 9.7 million deaths from cancer in 2022. The increasing adoption of cancer treatments such as "https://meditechinsights.com/car-t-cell-therapy-market/">CAR-T cell therapy, checkpoint inhibitors, and tumour vaccines requires accurate immune profiling for patient stratification and treatment optimization, thereby fueling the demand for IRS platforms.

Moreover, public and private organizations are significantly investing in precision oncology research, where immune repertoire analysis is becoming a standard analytical component. As oncology care moves toward data-driven and personalized treatment, IRS is becoming an essential resource for both biopharma companies and clinical research.

To learn more about this report, download the PDF brochure

Single-cell immune repertoire sequencing integrated with multi-omics platforms gains momentum

One of the most notable trends in the immune repertoire sequencing market is the growing integration of single-cell sequencing with multi-omics platforms, including transcriptomics, proteomics, and epigenomics. It enables better profiling of adaptive immunity as compared to traditional IRS techniques. By linking receptor sequences with functional and phenotypic data at the single-cell level, researchers can more accurately map immune behaviour in complex disease environments. This technique is particularly beneficial in oncology and immunotherapy development, as it supports the identification of tumour-reactive immune cells or weak T-cell states, thereby improving therapy selection and biomarker discovery.

Moreover, the surge in R&D activities in immunology following the pandemic has accelerated this trend, as governments and biotech firms are making significant investments in understanding immunological memory, disease resistance, and vaccination responses. Research laboratories and CROs are increasingly adopting the multi-omics platforms to combine receptor sequencing with other genetic markers. Additionally, advancements in AI-enabled software for multi-omics integration are making this approach more accessible. As a result, adoption of integrated multi-omics platforms is gaining momentum across both academic and commercial research environments.

Competitive Landscape Analysis

The global immune repertoire sequencing market comprises of several well-established and emerging players, including QIAGEN N.V.; Takara Bio Inc.; Illumina, Inc.; Oxford Nanopore Technologies plc; Agilent Technologies Inc.; Thermo Fisher Scientific Inc.; 10x Genomics, Inc.; Danaher Corporation; Adaptive Biotechnologies Corporation; and Azenta Inc; among others. Key strategies adopted by these players include the development of advanced sequencing technologies, mergers and acquisitions, and investment in R&D to enhance sequencing solutions and meet growing global demand.

Get a sample report for competitive landscape analysis

Organic and inorganic growth strategies adopted by players to establish their foothold in the immune repertoire sequencing market

Players operating in this market are adopting both organic and inorganic growth strategies, such as collaborations and acquisitions, to garner market share. For instance,

• In February 2025, Oxford Nanopore expanded its collaboration with 10x Genomics to integrate 10x Genomics- Chromium GEM-X 3-/5- single-cell chemistries with Nanopore sequencing workflows, thereby strengthening its sequencing portfolio
• In July 2024, Illumina acquired Fluent BioSciences to incorporate its microfluidics-free PIPseq V single-cell analysis technology, enhancing Illumina-s multi-omics portfolio with scalable workflows ranging from 100 to 1 million cells

Report ScopeReport Metric Details Base Year Considered 2025 Historical Data 2024 - 2025 Forecast Period 2026 - 2031 Growth Rate 10% Market Drivers

• Advancements in sequencing technologies
• Expanding use of cancer immunotherapies
• Increasing government investments for genomics research
• Rising prevalence of chronic and infectious diseases
• Growing demand for autoimmune disease profiling

Attractive Opportunities

• Integration of sequencing techniques with multi-omics platforms
• Rising demand in organ transplant monitoring
• Growth potential in CRISP integrated platforms

Segment Scope Product, Technology, Application, and End-user Regional Scope

• North America (US & Canada)
• Europe (UK, Germany, France, Italy, Spain, Rest of Europe)
• Asia Pacific (China, India, Japan, Rest of Asia Pacific)
• Latin America
• Middle East & Africa

Key Companies Mapped QIAGEN N.V.; Takara Bio Inc.; Illumina, Inc.; Oxford Nanopore Technologies plc; Agilent Technologies Inc.; Thermo Fisher Scientific Inc.; 10x Genomics, Inc.; Danaher Corporation; Adaptive Biotechnologies Corporation; and Azenta Inc; among others Report Highlights Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

Global Immune Repertoire Sequencing Market Segmentation

This report by Medi-Tech Insights provides thesize of the global immune repertoire sequencing market at theregional- and country-level from 2024 to 2031. The report further segments the market based on product, technology, application, and end-user.

Market Size & Forecast (2024-2031), By Product, USD Million

• Assay Kit & Reagent
• TCR Kits
• BCR Kits
• Others
• Instruments
• Software
• Others

Market Size & Forecast (2024-2031), By Technology, USD Million

• Sequencing Technologies
• Bulk Sequencing Technologies
• Single-cell Sequencing Technologies
• Library Preparation Technologies
• Bioinformatics & Data Analysis Tec

Market Size & Forecast (2024-2031), By Application, USD Million

• Cancer Immunotherapy
• Autoimmune & Inflammatory Diseases
• Infectious Diseases
• Vaccine Development
• Transplantation
• Others

Market Size & Forecast (2024-2031), By End-user, USD Million

• Pharma & Biotech Companies
• Academic Institutions
• Contract Research Organizations
• Others

Market Size & Forecast (2024-2031), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa